Special Issue

Multidrug-Resistant Gram-Negative Bacteria Infections: Current Epidemiology, Prognosis and Treatment Options

Message from the Guest Editor

In the rapidly evolving world of infectious diseases, multidrug-resistant Gram-negative bacteria (MDR-GNB) infections present significant threats to global public health. Understanding the prognosis and outcomes of MDR-GNB infections is crucial for healthcare providers and policymakers alike. In this Special Issue, we welcome scholars to explore current epidemiology, prognosis, and treatment options for these infections, including but not limited to those caused by *Enterobacteriaceae, Pseudomonas aeruginosa*, and *Acinetobacter baumannii*. Areas of interest include:

- The latest advances in understanding the mechanisms of resistance and transmission dynamics, as well as novel approaches to combatting these pathogens.
- Evaluation of the efficacy of existing treatment options and the exploration of emerging strategies to effectively prevent and manage these infections.
- Addressing the need for enhanced surveillance and rapid diagnostic methods to monitor the spread of multidrug-resistant Gram-negative bacteria and support optimal clinical decision making in the optimization of treatment plans.

Guest Editor

Dr. Novella Carannante

Emergency Room Infection Disease, Cotugno Hospital AORN dei Colli, 80131 Naples, Italy

Deadline for manuscript submissions

31 January 2026

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/si/194324

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI